MX2019015410A - Una composicion de nanoemulsion de clobetasol de aceite en agua. - Google Patents

Una composicion de nanoemulsion de clobetasol de aceite en agua.

Info

Publication number
MX2019015410A
MX2019015410A MX2019015410A MX2019015410A MX2019015410A MX 2019015410 A MX2019015410 A MX 2019015410A MX 2019015410 A MX2019015410 A MX 2019015410A MX 2019015410 A MX2019015410 A MX 2019015410A MX 2019015410 A MX2019015410 A MX 2019015410A
Authority
MX
Mexico
Prior art keywords
oil
comprised
clobetasol
weight ratio
nanoemulsion
Prior art date
Application number
MX2019015410A
Other languages
English (en)
Inventor
Aquilue Javier Sanagustin
Gris María Del Carmen Lendínez
Gañán Maria Isabel Delgado
Original Assignee
Salvat Lab Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salvat Lab Sa filed Critical Salvat Lab Sa
Publication of MX2019015410A publication Critical patent/MX2019015410A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Colloid Chemistry (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se refiere a una composición de nanoemulsión de aceite en agua que tiene una fase acuosa continua y gotas de aceite dispersas, en donde la nanoemulsión comprende: (a) clobetasol; (b) uno o más componentes oleosos; y (c) uno o más tensoactivos; junto con uno o más excipientes o vehículos farmacéuticamente aceptables en los que: la osmolalidad de la nanoemulsión está comprendida desde 100 mOsm/kg hasta 500 mOsm/kg; el tamaño promedio de gota medido por dispersión dinámica de luz está comprendido desde 1 nm hasta 500 nm; la relación en peso entre los componentes oleosos y la suma de los componentes oleosos y uno o más tensoactivos está comprendida desde 0.001 hasta 0.5; la relación en peso entre el componente oleoso y el clobetasol está comprendida desde 1:1 hasta 200:1; y la relación en peso entre el tensoactivo y el clobetasol está comprendida desde 2:1 hasta 200:1. También se refiere a procedimientos para su preparación, a su uso como medicamento y en la profilaxis y/o tratamiento de enfermedades o afecciones inflamatorias.
MX2019015410A 2017-06-23 2018-01-18 Una composicion de nanoemulsion de clobetasol de aceite en agua. MX2019015410A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17382393 2017-06-23
PCT/EP2018/051218 WO2018233878A1 (en) 2017-06-23 2018-01-18 OIL NANOEMULSION COMPOSITION IN CLOBETASOL WATER

Publications (1)

Publication Number Publication Date
MX2019015410A true MX2019015410A (es) 2021-09-30

Family

ID=59285129

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019015410A MX2019015410A (es) 2017-06-23 2018-01-18 Una composicion de nanoemulsion de clobetasol de aceite en agua.

Country Status (32)

Country Link
US (1) US10857160B2 (es)
EP (1) EP3641728B9 (es)
JP (1) JP7065895B2 (es)
KR (1) KR102571107B1 (es)
CN (1) CN110944625B (es)
AU (1) AU2018288256B2 (es)
CA (1) CA3067657A1 (es)
CL (1) CL2019003707A1 (es)
CO (1) CO2020000026A2 (es)
CR (1) CR20200024A (es)
CY (1) CY1124193T1 (es)
DK (1) DK3641728T3 (es)
DO (1) DOP2019000307A (es)
EC (1) ECSP19089679A (es)
ES (1) ES2875851T3 (es)
HR (1) HRP20210865T1 (es)
HU (1) HUE055016T2 (es)
IL (1) IL271474B (es)
LT (1) LT3641728T (es)
MX (1) MX2019015410A (es)
MY (1) MY190953A (es)
PE (1) PE20200736A1 (es)
PH (1) PH12019550291A1 (es)
PL (1) PL3641728T3 (es)
PT (1) PT3641728T (es)
RU (1) RU2759901C2 (es)
SA (1) SA519410841B1 (es)
SG (1) SG11201912393XA (es)
SI (1) SI3641728T1 (es)
TW (1) TWI768056B (es)
WO (1) WO2018233878A1 (es)
ZA (1) ZA202000128B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024005726A1 (en) * 2022-06-30 2024-01-04 Ilko Ilac Sanayi Ve Ticaret A.S. Storage stable topical composition comprising clobetasol

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA966579B (en) * 1995-08-04 1998-02-02 Wakamoto Pharma Co Ltd O/W emulsion composition for eye drops.
CA2578594C (en) * 2004-08-31 2012-04-17 Connetics Australia Pty Ltd Microemulsion & sub-micron emulsion process & compositions
US8449867B2 (en) * 2004-08-31 2013-05-28 Stiefel Research Australia Pty Ltd Microemulsion and sub-micron emulsion process and compositions
FR2889662B1 (fr) * 2005-08-11 2011-01-14 Galderma Res & Dev Emulsion de type huile-dans-eau pour application topique en dermatologie
AU2009246870B2 (en) * 2008-05-14 2013-08-01 Otonomy, Inc. Controlled release corticosteroid compositions and methods for the treatment of otic disorders
US20110045050A1 (en) * 2009-08-24 2011-02-24 Atrium Medical Corporation Nanoemulsion formulations for direct delivery
WO2012053007A1 (en) * 2010-10-21 2012-04-26 Cadila Healthcare Limited Topical pharmaceutical compositions containing nanodroplets for the treatment psoriasis
US9789123B2 (en) * 2010-10-21 2017-10-17 Cadila Healthcare Limited Topical pharmaceutical compositions containing nanodroplets for the treatment of psoriasis
CN102283850B (zh) 2011-08-25 2013-04-10 西北农林科技大学 一种水包油型复方酮康唑纳米药物及其制备方法
US10413508B2 (en) * 2015-02-06 2019-09-17 R. P. Scherer Technologies, Llc Preparation of an oil-in-water emulsion for polymer stabilized pharmaceutical formulations
CN107257680A (zh) * 2015-03-05 2017-10-17 阿勒根公司 用于眼科药物递送的自乳化药物递送体系(sedds)
TWI773641B (zh) * 2015-05-08 2022-08-11 日商活效製藥股份有限公司 含有糖皮質類固醇（ｇｌｕｃｏｃｏｒｔｉｃｏｉｄｓ）之奈米微粒子之水性懸浮液劑
ES2812451T3 (es) * 2015-06-18 2021-03-17 Bausch Health Ireland Ltd Composiciones tópicas que comprenden un corticosteroide y un retinoide para tratar la psoriasis
WO2017037663A1 (en) 2015-09-02 2017-03-09 Cadila Healthcare Limited Topical compositions comprising corticosteroids

Also Published As

Publication number Publication date
EP3641728A1 (en) 2020-04-29
ES2875851T3 (es) 2021-11-11
KR102571107B1 (ko) 2023-08-25
CY1124193T1 (el) 2022-05-27
CA3067657A1 (en) 2018-12-27
PE20200736A1 (es) 2020-07-23
MY190953A (en) 2022-05-24
AU2018288256B2 (en) 2023-09-28
TW201904562A (zh) 2019-02-01
DOP2019000307A (es) 2020-03-15
CO2020000026A2 (es) 2020-04-24
KR20200019945A (ko) 2020-02-25
EP3641728B1 (en) 2021-03-10
AU2018288256A1 (en) 2020-01-30
PH12019550291A1 (en) 2021-01-11
IL271474B (en) 2022-09-01
US20190298737A1 (en) 2019-10-03
RU2019144015A (ru) 2021-07-23
JP2020524672A (ja) 2020-08-20
HUE055016T2 (hu) 2021-10-28
ZA202000128B (en) 2021-01-27
PT3641728T (pt) 2021-06-14
RU2759901C2 (ru) 2021-11-18
CR20200024A (es) 2020-03-12
CN110944625B (zh) 2022-05-03
US10857160B2 (en) 2020-12-08
IL271474A (en) 2020-01-30
HRP20210865T1 (hr) 2021-08-20
LT3641728T (lt) 2021-08-10
EP3641728B9 (en) 2021-06-30
DK3641728T3 (da) 2021-06-07
PL3641728T3 (pl) 2021-09-20
WO2018233878A1 (en) 2018-12-27
JP7065895B2 (ja) 2022-05-12
CL2019003707A1 (es) 2020-06-05
TWI768056B (zh) 2022-06-21
SG11201912393XA (en) 2020-01-30
SA519410841B1 (ar) 2022-06-05
CN110944625A (zh) 2020-03-31
SI3641728T1 (sl) 2021-08-31
RU2019144015A3 (es) 2021-07-23
ECSP19089679A (es) 2020-05-29

Similar Documents

Publication Publication Date Title
MX2022014313A (es) Formulaciones para administracion oral de agentes activos con perfil de absorcion controlada.
MY156858A (en) Low-oil pharmaceutical emulsion compositions comprising progestogen
MX365657B (es) Composición novedosa y método de uso para controlar patógenos y prevenir enfermedades en semillas.
BR112018067586A2 (pt) composição administrável oralmente
AR075412A1 (es) Composiciones para el aseo personal que comprenden preparaciones especificas de aceites constituidos por trigliceridos saturados hidrogenados, con relacion a aceites insaturados metodo de preparacion
AR104835A1 (es) Composiciones nutricionales que contienen un nivel elevado de inositol y uso de las mismas
JP2010538011A5 (es)
PE20080658A1 (es) Formulaciones de metilnaltrexona en forma de polvo seco
NZ723838A (en) Cannabinoid compositions and uses
BR112014028069A2 (pt) composição farmacêutica oftálmica, processo para a preparação de uma composição farmacêutica oftálmica, uso de uma composição farmacêutica oftálmica, e, método para a prevenção ou tratamento de uma infecção fúngica
AR079639A1 (es) Composicion de pasta de dientes anti-erosiva
CO2019005156A2 (es) Composición para el tratamiento y/o prevención de la enfermedad fúngica sigatoka negra en los cultivos de banana
SA519410841B1 (ar) تركيبة مستحلب نانو زيت في ماء من كلوبيتاسول
CO2021016029A2 (es) Composición de partículas que contienen cocristal de ácido málico y malato de hidrógeno de metal alcalino
EP4103692A4 (en) NEW ANALOGS OF TDZD AS AGENTS THAT DELAY, PREVENT OR REVERSE AGE-ASSOCIATED DISEASES; AND AS ANTI-CANCER AND ANTILEUKEMIC AGENTS
FI3302451T3 (fi) Palmitoyylietanoliamidia (pea) ja lykopeenia sisältävä yhdistelmä käytettäväksi inflammatoristen sairauksien hoidossa
WO2017152130A8 (en) Pharmaceutical compositions
PE20211198A1 (es) Metodos y formulaciones para tratar nauseas y vomitos inducidos por quimioterapia
WO2019044529A8 (en) Oil-in-water emulsion composition comprising ether oil
WO2012039768A3 (en) Itraconazole formulations
AR108792A1 (es) Composiciones que comprenden timolol
JP2018515575A5 (es)
PH12019500473A1 (en) Solid composition for quick ingestion with facilitated swallowing, in the form of solid, non-agglomerated particles, comprising two different types of particles
DENG Application of dexmedetomidine in elderly patients during ESD operation
Pavliak et al. www. fasebj. org